Intervenciones farmacológicas en el marco de la diálisis peritoneal: protegiendo el peritoneo

The fluids used in the treatment of peritoneal dialysis (PD) as renal replacement therapy are inevitably bioincompatible due to their composition. These fluids may harm the peritoneal membrane, leading to inflammation, angiogenesis, vasodilatation, loss of mesothelial cells, epithelial-to-mesenchymal transition of these cells, fibrosis, encapsulating peritoneal sclerosis and membrane failure. Both experimental studies and clinical trials have investigated distinct mechanisms to reduce these effects, whether through the search for new biocompatible fluids or through the use of distinct drugs, administered intra- or extraperitoneally. In this article, we analyze the distinct studies performed in these 3 areas. The contribution of these types of study is essential to understand and improve the preservation of the peritoneum in order to optimize the technique of PD.